Conclusions: MAGE-A expression in blood or bone marrow at tumor surgery is an independent predictor of survival in resected NSCLC. The reliable prediction of distant metastasis in individual patients with a statistically proven impact on overall survival may help to refine patient selection for adjuvant therapy urgently needed especially in the clinical management of elderly patients.
For MRD assessment in NSCLC and other solid tumors several members of family A of melanoma-associated antigens (MAGE-A) are available as PCR markers of similarly high tumor specificity (6) . The MAGE-A gene family has 15 members located on chromosome Xq28 (7-9). The MAGE-A gene family belongs to the family of Cancer/Testis(CT)-antigens, which are normally restricted in their adult tissue expression to testis and placenta (10) and expressed briefly during early embryonic development (11) . In tumor cells, genome-wide epigenetic reprogramming frequently leads to activation of MAGE-A expression through promoter hypo-methylation (12 addition, other chromatin remodeling events like histone acetylation and methylation further modulate MAGE-A expression. While little is understood of the physiological function of MAGE-A proteins, there is more clarity on their role in promoting malignancy. MAGE-A proteins interfere with two major tumor suppressor mechanisms: By suppressing p53-mediated transcription they inhibit both p53-mediated apoptosis and senescence (13) . Moreover, by targeting the p53 pathway, MAGE-A proteins confer resistance to chemotherapeutic drugs that act via p53-mediated apoptosis (14) .
Most types of solid tumors including NSCLC frequently express at least one out of several MAGE-A family members (15, 16) . Therefore we used an established quantitative multimarker real-time reverse transcription (RT)-PCR for transcript amplification of MAGE-A1, -A2, -A3/6, -A4, -A10 and -A12 (17) in a proof-of-concept study designed to investigate whether the MAGE-A expression level in blood or bone marrow at the time of tumor surgery is an independent predictor of survival in patients with resected NSCLC. We tested the hypothesis, that detection of systemic MAGE expression in blood and/or bone marrow aspirates is associated with the formation of distant metastasis and cancer-related death. Furthermore, the protocol was designed to determine a quantitative cut-off value of MAGE expression in patients with disseminated tumor load in NSCLC, as distinct expression levels have not been examined before.
Research. abdominal ultrasound, and bronchoscopy at 6-month interval. In addition, family practitioners were contacted to obtain information about locoregional relapse, distant metastasis, and death. The median observation period was 43 months (range 1 -95 months).
PATIENTS AND METHODS

Trial design
The primary study endpoint was postoperative distant-metastasis-free survival defined as the postoperative time to distant metastasis without prior locoregional recurrence. Secondary endpoints were locoregional-recurrence-free, cancer-free and overall survival defined as the postoperative time to locoregional recurrence without prior distant metastasis, to any locoregional recurrence or distant metastasis and to death from any cause, respectively.
Quantitative multimarker MAGE real-time RT-PCR
The multimarker MAGE real-time RT-PCR was described elsewhere (6, 17) . The 
RESULTS
Characteristics of the patients
116 patients with suspected lung cancer were enrolled in the study (a patient flow diagram is depicted in Figure S1 in the supplement). According to postoperative assessment, 94 patients with histopathologically confirmed non-small cell lung cancer (NSCLC) fulfilled the inclusion criteria. 22 patients dropped out because of a benign histology such as tuberculosis or pneumonia (n=5), small-cell lung cancer (n=4) or due to incomplete tumor (R2) resection (n=13). Nine patients were included in whom ipsilateral intrapulmonary secondary lesions were found during tumor surgery, which could be removed in parallel. Clinicopathological characteristics are shown in Table   1 . Seven patients had microscopic residual tumor at the bronchial margin (R1 resection). The median age at the time of surgery was 66 years (range, 44 -82 years). Follow-up information was available for 89 of 94 patients (94.7%). The median observation period was 43 months (range 1 -95 months). 49 patients died within the observation period (55.1%). Table 2 shows treatment failures according to site of recurrence and MAGE-A expression level in bone marrow or blood.
MAGE-A expression in blood and bone marrow
In total, 1848 expression profiles of seven MAGE-A genes in 264 bone marrow and blood samples of 94 patients were created (Supplementary Table S1 ). 15 expression and tumor extension, grading, histology, lymph node status or age of the patients ( Table 1) .
Correlation of MAGE-A expression with survival
To determine the impact of different MAGE-A expression levels in bone marrow or blood on patients` clinical outcome according to the primary endpoint, the distantmetastasis-free survival of patients with a MAGE-A expression level at or above a certain threshold value in at least one sample of bone marrow or blood was (Figure 1, A) . The corresponding 5-year Kaplan-Meier estimates of distant-metastasis-free survival were 87% (95%CI ±10%) for patients with MAGE-A expression < 0.2 versus 43% (95%CI ±11%) for ≥ 0.2.
As to the secondary endpoints, log-rank tests revealed a significantly reduced cancer-free survival (p=0.002) and overall survival (p=0.007) between the two patient subgroups (≥ 0.2 vs. < 0.2) (Figure 1, B and C) 
Meier estimates of overall survival were 59% (95%CI ±14%) for patients with MAGE-A expression < 0.2 versus 26% (95%CI ±8%) for ≥ 0.2. The corresponding estimates for cancer-free survival were 69% (95%CI ±14%) versus 31% (95%CI ±18%).
In contrast to the strong correlation of MAGE-A ≥ 0.2 in bone marrow or blood with the development of distant metastasis, there was no significant difference in locoregional-recurrence-free survival (p=0.26, log-rank test) between patients with MAGE-A ≥ 0.2 in bone marrow or blood and patients below 0.2 in all samples (Figure   1, D) .
In the subgroup of patients with R1 resection (n=7) three patients died due to local Table 4 :
Multivariable hazard ratios for overall survival, cancer-free survival and distant metastasis-free survival 
